Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab open-label extension in moderately to severely active rheumatoid arthritis
2015-005309-35Phase 3Unknown
- Sponsor
- R-Pharm
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of olokizumab in rheumatoid arthritis (RA) (2 arms), sponsored by R-Pharm. Primary endpoint: Long-term safety and tolerability. Status: unknown.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-005309-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005309-35.